参考文献

[1] World Health Organization. Coronavirus Disease (COVID-19) Dashboard. https://covid19.who.int/

[2]中国疾病预防控制中心.全国艾滋病检测技术规范（2020年修订版）. http://ncaids.chinacdc.cn/tzgggd/202005/t20200518_216798.htm

[3] Gao GJ, Wang AB, Wang S. A retrospective evaluation on the efficacy of Lopinavir/ritonavir and chloroquine to treat non-severe COVID-19 patients. JAIDS.

[4] 国家卫生健康委.新型冠状病毒肺炎诊疗方案（试行第八版）. http://www.nhc.gov.cn/yzygj/s7653p/202008/0a7bdf12bd4b46e5bd28ca7f9a7f5e5a.shtml

[5] 陈方方, 汤后林, 吕繁. 新型冠状病毒肺炎对HIV感染人群影响的研究进展. 中华流行病学杂志, 2020. [网络预发表].

[6] Guan WJ, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med, 2020.

[7] World Health Organization. Coronavirus disease (COVID-2019) advice for the public: myth busters https://www.who.int/emergencies/diseases/novel-coronavirus-2019/advice-for-public/myth-busters.

[8] UNAIDS. What people living with HIV need to know about HIV and COVID-19. https://www.unaids.org/en/covid19.

[9]陈方方, 汤后林, 吕繁. 新型冠状病毒肺炎对HIV感染人群影响的研究进展. 中华流行病学杂志, 2020, 41 (0): E074. DOI: 10.3760/cma.j.cn112338-20200603-00803. [网络预发表].